APEIRON Biologics is involved in developing cancer immunotherapy products, including the drug Qarziba®, which has received market approval.

APEIRON Biologics

APEIRON Biologics AG | 4,166 followers on LinkedIn. Improving the lives of patients with next generation therapies for cancer and respiratory disease, including COVID-19. | APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies.  

Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients.

Attoquant Diagnostics GmbH

Marko Poglitsch

APEI

COM:APEIRON-BIOLOGICS

APEIRON Biologics